Literature DB >> 26045739

Reduced beta 2 glycoprotein I improves diabetic nephropathy via inhibiting TGF-β1-p38 MAPK pathway.

Tong Wang1, Si-Si Chen1, Rui Chen1, De-Min Yu1, Pei Yu1.   

Abstract

PURPOSE: Beta 2 glycoprotein I (β2GPI) has been shown the positive effect on diabetic atherosclerosis and retinal neovascularization. β2GPI can be reduced by thioredoxin-1, resulting in the reduced state of β2GPI. The possible protective effects of β2GPI and reduced β2GPI on diabetic nephropathy (DN) are not fully elucidated. The purpose of this study was to test a hypothesis that β2GPI and reduced β2GPI would improve DN in streptozotocin (STZ) induced diabetic mice and high-glucose (HG) exposed rat mesangial cell (RMC).
METHODS: The STZ-induced Balb/c mice and HG exposed RMCs were administrated with β2-GPI and reduced β2-GPI at different time and concentrations gradient respectively. The changes of glomerular structure and expression of collagen IV, TGF-β1, p38 MAPK and phospho-p38 MAPK in renal cortical and mesangial cells were observed by immunohistochemical techniques, quantitative real-time PCR and western blot with or without the treatment of β2-GPI and reduced β2-GPI.
RESULTS: β2GPI and reduced β2GPI improved early clinical and pathological changes of DN in STZ-diabetic mice. Treatment with β2GPI and reduced β2GPI in the STZ-diabetic mice and HG exposed RMCs resulted in decrease expression levels of TGF-β1 and collagen IV, with concomitant decrease in phospho-p38 MAPK expression.
CONCLUSIONS: β2GPI and reduced β2GPI improved renal structural damage and kidney function. The renoprotective and antifibrosis effects of β2GPI and reduced β2GPI on DN were closely associated with suppressing the activation of the TGF-β1-p38 MAPK pathway.

Entities:  

Keywords:  Beta 2 glycoprotein I; TGF-β1; diabetic nephropathy

Mesh:

Substances:

Year:  2015        PMID: 26045739      PMCID: PMC4440048     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  28 in total

1.  Evolutionary conservation of the lipopolysaccharide binding site of β₂-glycoprotein I.

Authors:  Çetin Ağar; Philip G de Groot; J Arnoud Marquart; Joost C M Meijers
Journal:  Thromb Haemost       Date:  2011-09-22       Impact factor: 5.249

2.  TGF-beta1 activates MAP kinase in human mesangial cells: a possible role in collagen expression.

Authors:  T Hayashida; A C Poncelet; S C Hubchak; H W Schnaper
Journal:  Kidney Int       Date:  1999-11       Impact factor: 10.612

Review 3.  Pathogenesis of diabetic nephropathy.

Authors:  A E Raptis; G Viberti
Journal:  Exp Clin Endocrinol Diabetes       Date:  2001       Impact factor: 2.949

4.  High glucose increases inducible NO production in cultured rat mesangial cells. Possible role in fibronectin production.

Authors:  Hyunjin Noh; Hunjoo Ha; Mi Ra Yu; Shin Wook Kang; Kyu Hun Choi; Dae Suk Han; Ho Yung Lee
Journal:  Nephron       Date:  2002-01       Impact factor: 2.847

5.  Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome.

Authors:  R Schwarzenbacher; K Zeth; K Diederichs; A Gries; G M Kostner; P Laggner; R Prassl
Journal:  EMBO J       Date:  1999-11-15       Impact factor: 11.598

Review 6.  β(2) -Glycoprotein I: evolution, structure and function.

Authors:  P G de Groot; J C M Meijers
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

Review 7.  TGF-β signaling via TAK1 pathway: role in kidney fibrosis.

Authors:  Mary E Choi; Yan Ding; Sung Il Kim
Journal:  Semin Nephrol       Date:  2012-05       Impact factor: 5.299

8.  Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster.

Authors:  Milosz Jankowski; Ingrid Vreys; Christine Wittevrongel; Doris Boon; Jos Vermylen; Marc F Hoylaerts; Jef Arnout
Journal:  Blood       Date:  2002-09-05       Impact factor: 22.113

9.  Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I.

Authors:  Yiannis Ioannou; Jing-Yun Zhang; Miao Qi; Lu Gao; Jian Cheng Qi; De-Min Yu; Herman Lau; Allan D Sturgess; Panayiotis G Vlachoyiannopoulos; Haralampos M Moutsopoulos; Anisur Rahman; Charis Pericleous; Tatsuya Atsumi; Takao Koike; Stephane Heritier; Bill Giannakopoulos; Steven A Krilis
Journal:  Arthritis Rheum       Date:  2011-09

10.  C-reactive protein/oxidised low-density lipoprotein/β2-glycoprotein I complex promotes atherosclerosis in diabetic BALB/c mice via p38mitogen-activated protein kinase signal pathway.

Authors:  Rui Zhang; Sai-Jun Zhou; Chun-Jun Li; Xiao-Nan Wang; Yun-Zhao Tang; Rui Chen; Lin Lv; Qian Zhao; Qiu-Ling Xing; De-Min Yu; Pei Yu
Journal:  Lipids Health Dis       Date:  2013-03-26       Impact factor: 3.876

View more
  4 in total

1.  Reduced beta 2 glycoprotein I prevents high glucose-induced cell death in HUVECs through miR-21/PTEN.

Authors:  Jing-Yun Zhang; Jun Ma; Pei Yu; Guang-Jie Tang; Chun-Jun Li; De-Min Yu; Qiu-Mei Zhang
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

2.  High glucose/lysophosphatidylcholine levels stimulate extracellular matrix deposition in diabetic nephropathy via platelet‑activating factor receptor.

Authors:  Su-Xian Zhou; Dong-Mei Huo; Xiao-Yun He; Ping Yu; Yan-Hua Xiao; Chun-Lin Ou; Ren-Mei Jiang; Dan Li; Hao Li
Journal:  Mol Med Rep       Date:  2017-11-20       Impact factor: 2.952

3.  Reduced β2GPI Inhibiting Glomerular Mesangial Cells VEGF-NO Axis Uncoupling Induced by High Glucose.

Authors:  Zhou Saijun; Li Xin; Wang Jie; Xiao Shumin; Liu Shuaihui; Yu Pei
Journal:  Biomed Res Int       Date:  2018-07-18       Impact factor: 3.411

4.  Protective Effects of Reduced Beta 2 Glycoprotein I on Liver Injury in Streptozotocin (STZ)-Diabetic Rats by Activation of AMP-Activated Protein Kinase.

Authors:  Jing-Yun Zhang; Chun-Jun Li; Qiu-Mei Zhang; Pei Yu; Jian-Ying Shi; Guang-Jie Tang; Lin-Lin Ma; De-Min Yu
Journal:  Med Sci Monit       Date:  2018-10-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.